AU2001246934A1 - Agonist antibodies - Google Patents

Agonist antibodies

Info

Publication number
AU2001246934A1
AU2001246934A1 AU2001246934A AU4693401A AU2001246934A1 AU 2001246934 A1 AU2001246934 A1 AU 2001246934A1 AU 2001246934 A AU2001246934 A AU 2001246934A AU 4693401 A AU4693401 A AU 4693401A AU 2001246934 A1 AU2001246934 A1 AU 2001246934A1
Authority
AU
Australia
Prior art keywords
agonist antibodies
agonist
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001246934A
Inventor
Naoshi Fukushima
Yasufumi Kikuchi
Masayoshi Oh-Eda
Toshihiko Ohtomo
Masayuki Tsuchiya
Shinsuke Uno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2001/001912 external-priority patent/WO2001066737A1/en
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2001246934A1 publication Critical patent/AU2001246934A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AU2001246934A 2000-04-17 2001-04-17 Agonist antibodies Abandoned AU2001246934A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP2000-115246 2000-04-17
JP2000115246 2000-04-17
JP2000-321822 2000-10-20
JP2000-321821 2000-10-20
JP2000321822 2000-10-20
JP2000321821 2000-10-20
PCT/JP2001/001912 WO2001066737A1 (en) 2000-03-10 2001-03-12 Polypeptide inducing apoptosis
WOJP01/01912 2001-03-12
PCT/JP2001/003288 WO2001079494A1 (en) 2000-04-17 2001-04-17 Agonist antibodies

Publications (1)

Publication Number Publication Date
AU2001246934A1 true AU2001246934A1 (en) 2001-10-30

Family

ID=27455291

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001246934A Abandoned AU2001246934A1 (en) 2000-04-17 2001-04-17 Agonist antibodies

Country Status (2)

Country Link
AU (1) AU2001246934A1 (en)
WO (1) WO2001079494A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
DE60133479T2 (en) 2000-10-20 2009-04-16 Chugai Seiyaku K.K. MODIFIED TPO AGONISTS ANTIBODIES
US7732149B2 (en) 2002-04-26 2010-06-08 Chugai Seiyaku Kabushiki Kaisha Methods of screening agonistic antibodies
JP2004279086A (en) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc Radiation image conversion panel and method for manufacturing it
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
US20070281327A1 (en) * 2003-12-12 2007-12-06 Kiyotaka Nakano Methods of Screening for Modified Antibodies With Agonistic Activities
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
WO2006106903A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
KR101360671B1 (en) 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 Pharmaceutical compositions containing sc(Fv)2
KR101367544B1 (en) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 Stabilizer for protein preparation comprising meglumine and use thereof
WO2006132341A1 (en) * 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 SITE-DIRECTED MUTANT
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
SG10201803449VA (en) 2013-09-27 2018-05-30 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
KR20010023866A (en) * 1997-09-11 2001-03-26 나가야마 오사무 Monoclonal antibody inducing apoptosis
AU2940900A (en) * 1999-03-10 2000-09-28 Chugai Seiyaku Kabushiki Kaisha Single-stranded fv inducing apoptosis

Also Published As

Publication number Publication date
WO2001079494A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
AU2002210918A1 (en) Degraded agonist antibody
AU1091802A (en) Degraded agonist antibody
AU2002256895A1 (en) Anti-TRAIL-R antibodies
AU2002210917A1 (en) Degraded TPO agonist antibody
AU1290001A (en) Antibodies
HUP0300841A3 (en) Agonist anti-trk-c monoclonal antibodies
AU2001240819A1 (en) Proteomics database
AU1091702A (en) Degraded tpo agonist antibody
AU2001234125A1 (en) Antibody library
AU4935000A (en) Antibodies
AU2002365649A1 (en) Anti-dota antibody
AU2001246934A1 (en) Agonist antibodies
AU2001239773A1 (en) Baroplastic materials
AU2001265871A1 (en) Substituted sulfonylaminopyrimidines
AU2001254731A1 (en) Substituted phenyluracils
AU2001258255A1 (en) Substituted benzoylcyclohexenones
AU2001220281A1 (en) Rollerboard for road-skiing
AU2002239291A1 (en) G protein coupled receptors
AU2001266176A1 (en) Methods
AU8293201A (en) Applause device
AU2002221132A1 (en) Novel antibody
AU2001223882A1 (en) Receptor
AU2002239747A1 (en) Cystoskeleton-associated proteins
AU2001244863A1 (en) Apoptin-associating protein
AU2001250536A1 (en) Methods